276 related articles for article (PubMed ID: 23492366)
1. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
Burkhardt L; Fuchs S; Krohn A; Masser S; Mader M; Kluth M; Bachmann F; Huland H; Steuber T; Graefen M; Schlomm T; Minner S; Sauter G; Sirma H; Simon R
Cancer Res; 2013 May; 73(9):2795-805. PubMed ID: 23492366
[TBL] [Abstract][Full Text] [Related]
2. ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci.
Tereshchenko IV; Zhong H; Chekmareva MA; Kane-Goldsmith N; Santanam U; Petrosky W; Stein MN; Ganesan S; Singer EA; Moore D; Tischfield JA; DiPaola RS
Prostate; 2014 Nov; 74(15):1551-9. PubMed ID: 25175909
[TBL] [Abstract][Full Text] [Related]
3. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
4. Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation.
Metzger E; Willmann D; McMillan J; Forne I; Metzger P; Gerhardt S; Petroll K; von Maessenhausen A; Urban S; Schott AK; Espejo A; Eberlin A; Wohlwend D; Schüle KM; Schleicher M; Perner S; Bedford MT; Jung M; Dengjel J; Flaig R; Imhof A; Einsle O; Schüle R
Nat Struct Mol Biol; 2016 Feb; 23(2):132-9. PubMed ID: 26751641
[TBL] [Abstract][Full Text] [Related]
5. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
6. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
7. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
8. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
9. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
[TBL] [Abstract][Full Text] [Related]
12. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
13. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness.
Huang S; Gulzar ZG; Salari K; Lapointe J; Brooks JD; Pollack JR
Oncogene; 2012 Sep; 31(37):4164-70. PubMed ID: 22179824
[TBL] [Abstract][Full Text] [Related]
14.
Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
[TBL] [Abstract][Full Text] [Related]
15. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.
Liu W; Lindberg J; Sui G; Luo J; Egevad L; Li T; Xie C; Wan M; Kim ST; Wang Z; Turner AR; Zhang Z; Feng J; Yan Y; Sun J; Bova GS; Ewing CM; Yan G; Gielzak M; Cramer SD; Vessella RL; Zheng SL; Grönberg H; Isaacs WB; Xu J
Oncogene; 2012 Aug; 31(35):3939-48. PubMed ID: 22139082
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
19. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
Scheble VJ; Braun M; Beroukhim R; Mermel CH; Ruiz C; Wilbertz T; Stiedl AC; Petersen K; Reischl M; Kuefer R; Schilling D; Fend F; Kristiansen G; Meyerson M; Rubin MA; Bubendorf L; Perner S
Mod Pathol; 2010 Aug; 23(8):1061-7. PubMed ID: 20473283
[TBL] [Abstract][Full Text] [Related]
20. ERG gene rearrangements are common in prostatic small cell carcinomas.
Lotan TL; Gupta NS; Wang W; Toubaji A; Haffner MC; Chaux A; Hicks JL; Meeker AK; Bieberich CJ; De Marzo AM; Epstein JI; Netto GJ
Mod Pathol; 2011 Jun; 24(6):820-8. PubMed ID: 21336263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
